Kymera Therapeutics operates with a specialized, highly focused workforce consisting of approximately 190 to 210 dedicated biotechnology professionals, clinical researchers, and laboratory scientists. Headquartered in Watertown, Massachusetts, the clinical-stage biopharmaceutical enterprise utilizes its lean, expert team to pioneer targeted protein degradation platforms and advance novel small-molecule therapeutics designed to treat immunological diseases and complex oncology indications through targeted protein breakdown.